

Gibson Dunn Advises Royalty Pharma on Acquisition of Royalty Interest in Amgen's Imdelltra

Firm News | August 26, 2025

Gibson Dunn is representing Royalty Pharma plc in its acquisition of a royalty interest in Amgen's Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), from BeOne Medicines for up to \$950 million.

Royalty Pharma will pay \$885 million upfront, and BeOne retains the option to sell an additional portion of its royalty to Royalty Pharma for up to \$65 million within the next 12 months, in exchange for an approximately 7% royalty on worldwide net sales of Imdelltra.

Our corporate team includes partners Karen Spindler, Ryan Murr, and associate Ayushi Sutaria.

Related People

[Karen A. Spindler](#)

[Ryan A. Murr](#)

[Ayushi Sutaria](#)

Related Capabilities

[Mergers and Acquisitions](#)

[Life Sciences](#)

[Public Companies](#)